Related Experiment Video
Updated: May 17, 2026

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
Published on: January 7, 2016
The cardiovascular system in growth hormone excess and growth hormone deficiency
G Lombardi1, C Di Somma, L F S Grasso
1Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy. gaelomba@unina.it
Insights
Growth hormone (GH) excess (acromegaly) and deficiency (GHD) significantly increase cardiovascular risks. Managing GH/IGF-I levels improves heart health and life expectancy in these patients.
Area of Science:
- Endocrinology
- Cardiovascular Medicine
- Metabolic Disorders
Background:
- Growth hormone (GH) and insulin-like growth factor-I (IGF-I) imbalances are linked to cardiovascular disease.
- Acromegaly (GH excess) and GH deficiency (GHD) present distinct cardiovascular risks.
Purpose of the Study:
- To summarize the cardiovascular implications of GH excess and deficiency.
- To highlight the impact of disease control and hormone replacement on cardiovascular outcomes.
Main Methods:
- Review of clinical conditions associated with GH excess and deficiency.
- Analysis of cardiovascular morbidity and mortality in acromegaly and GHD.
- Evaluation of treatment effects on cardiovascular parameters.
Main Results:
- GH excess causes specific cardiomyopathy, hypertension, diabetes, dyslipidemia, and atherosclerosis.
- GHD is associated with altered body composition, lipid profiles, insulin resistance, endothelial dysfunction, and atherosclerosis.
- Disease control in acromegaly and GH replacement in GHD improve cardiovascular risk factors and cardiac function.
Conclusions:
- Acromegaly and GHD significantly increase cardiovascular morbidity and mortality.
- Effective management of GH/IGF-I secretion normalizes cardiovascular abnormalities and life expectancy.
Abstract:
The clinical conditions associated with GH excess and GH deficiency (GHD) are known to be associated with an increased risk for the cardiovascular morbidity and mortality, suggesting that either an excess or a deficiency in GH and/or IGF-I is deleterious for cardiovascular system. In patients with acromegaly, chronic GH and IGF-I excess commonly causes a specific cardiomyopathy characterized by a concentric cardiac hypertrophy associated with diastolic dysfunction and, in later stages, with systolic dysfunction ending in heart failure if GH/IGF-I excess is not controlled. Abnormalities of cardiac rhythm and anomalies of cardiac valves can also occur. Moreover, the increased prevalence of cardiovascular risk factors, such as hypertension, diabetes mellitus, and insulin resistance, as well as dyslipidemia, confer an increased risk for vascular atherosclerosis. Successful control of the disease is accompanied by a decrease of the cardiac mass and improvement of cardiac function and an improvement in cardiovascular risk factors. In patients with hypopituitarism, GHD has been considered the under- lying factor of the increased mortality when appropriate standard replacement of the pituitary hormones deficiencies is given. Either childhood-onset or adulthood-onset GHD are characterized by a cluster of abnormalities associated with an increased cardiovascular risk, including altered body composition, unfavorable lipid profile, insulin resistance, endothelial dysfunction and vascular atherosclerosis, a decrease in cardiac mass together with an impairment of systolic function mainly after exercise. Treatment with recombinant GH in patients with GHD is followed by an improvement of the cardiovascular risk factors and an increase in cardiac mass together with an improvement in cardiac performance. In conclusion, acromegaly and GHD are associated with an increased risk for cardiovascular morbidity and mortality, but the control of GH/IGF-I secretion reverses cardiovascular abnormalities and restores the normal life expectancy.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cellular Adaptation II: Hypertrophy
Regulation of the Cardiovascular System
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...
Cardiovascular System Abnormal Findings I: Inspection and Palpation
Abnormal findings observed during an inspection
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Pathophysiology of Heart Failure